Sysmex (OTCMKTS:SSMXY) Cut to Hold at Citigroup

Citigroup lowered shares of Sysmex (OTCMKTS:SSMXY) from a strong-buy rating to a hold rating in a research report sent to investors on Monday,Zacks.com reports.

Sysmex Stock Performance

OTCMKTS:SSMXY opened at $8.61 on Monday. The company has a market cap of $5.42 billion, a price-to-earnings ratio of 17.94 and a beta of 1.14. Sysmex has a 1 year low of $8.15 and a 1 year high of $19.65. The stock’s 50 day simple moving average is $9.33 and its two-hundred day simple moving average is $10.45. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.33 and a quick ratio of 2.44.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Thursday, February 12th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The firm had revenue of $837.32 million during the quarter, compared to analyst estimates of $819.99 million. Sysmex had a net margin of 8.86% and a return on equity of 9.27%. As a group, equities analysts anticipate that Sysmex will post 0.57 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.